PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26223F0021Iclusig ponatinib 45mg TAB for vasdhcs — Takeda Pharmaceuticals America, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Takeda Pharmaceuticals America, Inc

Recipient

Sep 30, 2023

PoP end

$153K

Obligated

$153K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Takeda Pharmaceuticals America, Inc — $90

Contract facts

Federal

Contract number36C26223F0021

Also listed as36C262-23-F-0021

Also listed as36F79718D0586-36C26223F0021

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentTakeda Pharmaceuticals America, Inc

CAGE3FLV7

UEIENNFDLWFC6L1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0586

Place of performanceEARTH CITY MO

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 16, 2022

PoP end (current)Sep 30, 2023

Obligated$153K

Current value$153K

Potential value$153K

ICLUSIG PONATINIB 45MG TAB FOR VASDHCS is a federal award for 262-Network Contract Office 22 (36C262) held by Takeda Pharmaceuticals America, Inc. Estimated value $153K ($153K obligated). Current period of performance ends Sep 30, 2023. Last award drew 1 bidder. Place of performance: EARTH CITY MO.

Recompete timing

Public

● Past PoP end (1056 days ago)

Current PoP ended Sep 30, 2023 (1056 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26223F0021?

36C26223F0021 (Iclusig ponatinib 45mg TAB for vasdhcs) is a 262-Network Contract Office 22 (36C262) award with a potential value of $153K, currently held by Takeda Pharmaceuticals America, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-23-F-0021?

36C262-23-F-0021 is the dashed form of PIID 36C26223F0021 (Iclusig ponatinib 45mg TAB for vasdhcs), held by Takeda Pharmaceuticals America, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26223F0021?

262-Network Contract Office 22 (36C262) awarded 36C26223F0021 to Takeda Pharmaceuticals America, Inc (potential $153K).

Who is the incumbent on 36C26223F0021?

Takeda Pharmaceuticals America, Inc is the incumbent. The current period of performance ends Sep 30, 2023.

When does Takeda Pharmaceuticals America, Inc’s 36C26223F0021 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Mar 28, 2023 · refreshed monthly